Physiomics plc (AIM: PYC) has secured a new £102,000 drug development modelling contract, taking the total value of contract awards announced since May 2026 to more than £970,000, exceeding the
Physiomics plc (AIM: PYC) has secured a new £102,000 drug development modelling contract, taking the total value of contract awards announced since May 2026 to more than £970,000, exceeding the
Physiomics plc (AIM: PYC) has secured a new £119,000 contract for drug development modelling while exploring additional commercial opportunities for its personalised dosing technology, including potential expansion into the US
Physiomics plc (AIM: PYC) reported its highest annual income since incorporation, with revenue and grant income rising 26.5% to £1.06 million in the year ended 30 June 2026.
Physiomics plc (AIM: PYC) has secured new contracts worth more than £205,000, extending a strong run of commercial wins for the mathematical modelling, data science and biostatistics specialist.
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces that Ian Bagnall, Director of the
Physiomics plc (AIM: PYC) has secured multiple new contract awards with a combined estimated value of more than £200,000.
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the promotion of
Physiomics (AIM: PYC) has provided a positive operational update, highlighting record commercial opportunities, cost savings and a clearer path towards profitability as the AIM-listed modelling and data science specialist executes
Physiomics plc (AIM: PYC) is one of those AIM microcaps that can easily be overlooked at first glance. The company operates in a specialist corner of the healthcare sector, providing
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to highlight the development of
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that so far
Physiomics plc (AIM: PYC) is one of those AIM microcaps that can easily be overlooked at first glance. The company operates in a specialist corner of the healthcare sector, providing